PHILADELPHIA –A national research study to focus on diet as a tool for managing Crohn’s disease symptoms, led by James Lewis, MD, MSCE, a professor of Medicine and Epidemiology at the Perelman School of Medicine at the University of Pennsylvania, on behalf of the Crohn’s & Colitis Foundation of America (CCFA), has been approved to receive a $2.5 million funding award by the Patient-Centered Outcomes Research Institute (PCORI).
The study, which will examine the effectiveness of the specific carbohydrate diet and the Mediterranean-style diet to induce remission in patients with Crohn’s disease, is the result of a patient-generated research question posed through CCFA’s patient-powered research network - CCFA Partners.
Crohn’s disease is a chronic, inflammatory bowel disease (IBD) which currently has no cure and affects more than 500,000 Americans. Existing therapies are not completely effective and are associated with substantial risks of side effects. For patients living with IBD, diet can be a difficult area to navigate. While not caused by eating any one particular food, certain foods may aggravate symptoms in some patients.
“There is little scientific evidence to guide how patients with Crohn’s should modify their diet. Because of this, patients and their physicians face substantial uncertainty about the best diet for Crohn’s,” said Lewis, the principal investigator for the study, and senior scholar in the Center for Clinical Epidemiology and Biostatistics at Penn. “This study will open the door to a more holistic treatment of Crohn’s disease and provide high quality data and guidance for incorporating diet modifications into the treatment of the disease.”
A major focus of CCFA Partners patient-powered research network is to develop a community of IBD citizen scientists partnering with researchers to develop and prioritize study ideas based on their own experiences and observations from living with IBD. Lewis drew from ulcerative colitis patient, and CCFA Partners’ patient governance committee member, Jessica Burris’ experience to formulate this study.
“Doctors often tell patients like me that when it comes to diet, everybody is different – what works for some may not work for others. However, few conclusions have been reached that identifies those differences and how they can be applied to clinical practice,” Burris said. “Dietary interventions must be studied as they have the potential to greatly impact the health and quality of life of individuals living with IBD’s like Crohn’s and ulcerative colitis.”
Consistent with the philosophy of the CCFA Partners patient-powered research network, a team of IBD patients will work with Lewis and other researchers throughout all stages of the study – protocol development, study conduct, analysis and interpretation of study data, and dissemination of research results.
“This project was selected for PCORI funding not only for its scientific merit and commitment to engaging patients and other stakeholders, but also for its potential to fill an important gap in our health knowledge and give people information to help them weigh the effectiveness of their care options,” said PCORI Executive Director Joe Selby, MD, MPH. “We look forward to following the study’s progress and working with Dr. Lewis and the CCFA to share the results.”
PCORI is an independent, non-profit organization authorized by Congress in 2010 to fund research that will provide patients, their caregivers and clinicians with the evidence-based information they need to make better-informed healthcare decisions.
PCORnet, the National Patient-Centered Clinical Research Network, is an innovative initiative of PCORI that aims to improve the nation’s capacity to conduct comparative clinical effectiveness research efficiently by creating a large, highly representative network for conducting clinical outcomes research that directly involves patients in the development and execution of research.
CCFA’s award has been approved pending completion of a business and programmatic review by PCORI staff and issuance of a formal award contact.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation’s first medical school) and the University of Pennsylvania Health System, which together form a $8.6 billion enterprise.
The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $494 million awarded in the 2019 fiscal year.
The University of Pennsylvania Health System’s patient care facilities include: the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center—which are recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report—Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; and Pennsylvania Hospital, the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is powered by a talented and dedicated workforce of more than 43,900 people. The organization also has alliances with top community health systems across both Southeastern Pennsylvania and Southern New Jersey, creating more options for patients no matter where they live.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2019, Penn Medicine provided more than $583 million to benefit our community.